Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Melan-A Double Nickase Plasmid (h): sc-418014-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Melan-A Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- Melan-A Double Nickase Plasmid (h) and Melan-A Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting MLANA. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Melan-A Antibody (A103): sc-20032
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Melan-A Double Nickase Plasmid (h) | sc-418014-NIC | 20 µg | $410.00 | |||
Melan-A Double Nickase Plasmid (h2) | sc-418014-NIC-2 | 20 µg | $410.00 |
MLANA encodes Melan-A (also known as MART-1), a melanocyte lineage–restricted protein that localizes to melanosomes and participates in melanosome maturation and melanogenesis. Its expression is regulated by transcriptional programs centered on MITF and is closely linked to pigmentation pathways and melanosomal protein trafficking. MLANA is widely used as a molecular marker of melanocytic differentiation and is frequently evaluated in studies of melanoma biology and cellular identity. Perturbation or altered expression of Melan-A informs research on pigment cell development, antigen processing, and melanocyte-to-melanoma state transitions.
Melan-A Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the MLANA locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within MLANA. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt MLANA function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of MLANA-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.